Chinese drug company Shenzhen Chipscreen Biosciences Co Ltd (SHA:688321) announced on Thursday that the Investigational New Drug (IND) application that it previously submitted to the Center for Drug Evaluation of National Medical Products Administration of China for CS231295 tablets, a Class 1 innovative drug for the treatment of tumours, has been accepted.
CS231295 is a novel brain-penetrating small-molecule, multi-target protein kinase inhibitor independently developed by Chipscreen Biosciences, with proprietary intellectual property rights. According to the company, this drug candidate exhibits significant synthetic lethal effects on tumours carrying particular genetic defects, providing a new treatment option for patients with such tumours.
CS231295 also demonstrates potent anti-tumour angiogenesis activity, resulting in wide-spectrum anti-tumour efficacy. In the future, CS231295, either as a monotherapy or in combination with other anti-tumour drugs, is expected to offer differentiated and innovative treatment options for various types of cancer.
In preclinical studies, the treatment has shown significant pharmacodynamic activity, favourable pharmacokinetic properties and a good safety profile.
TC BioPharm agrees research planning collaboration to develop Monkeypox treatment
Adcentrx Therapeutics' ADRX-0405 IND application approved by US FDA
Avacta Group partners with Tempus to enhance AI-driven oncology drug development
OncoZenge partners with Pharmanovia for exclusive BupiZenge commercialization in EMENA regions
SHINE Technologies collaboration could result in new kidney and prostate cancer treatments
Shenzhen Chipscreen Biosciences' IND application for CS231295 tablets accepted in China
Sanofi and Orano partner to advance radioligand therapies
RaySearch secures RayStation orders from French cancer centers under Unicancer agreement
HUTCHMED's TAGRISSO plus ORPATHYS shows promise in lung cancer treatment
Anixa Biosciences administers second dose of CAR-T therapy to individual patient
AtomVie Global Radiopharma partners with Radiopharm Ventures
Lipella granted patent for innovative drug delivery technology
RedHill Biopharma's opaganib selected for Ebola treatment development by BARDA